Chi Sheng Pharma & Biotech Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 5/6
Chi Sheng Pharma & Biotech has a total shareholder equity of NT$1.2B and total debt of NT$100.0M, which brings its debt-to-equity ratio to 8.3%. Its total assets and total liabilities are NT$1.8B and NT$582.7M respectively. Chi Sheng Pharma & Biotech's EBIT is NT$54.8M making its interest coverage ratio -3.5. It has cash and short-term investments of NT$440.6M.
Anahtar bilgiler
8.3%
Borç/özkaynak oranı
NT$100.00m
Borç
| Faiz karşılama oranı | -3.5x |
| Nakit | NT$440.62m |
| Eşitlik | NT$1.21b |
| Toplam yükümlülükler | NT$582.71m |
| Toplam varlıklar | NT$1.79b |
Son finansal sağlık güncellemeleri
Güncelleme yok
Recent updates
Read This Before Buying Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111) For Its Dividend
Apr 06
A Look At The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)
Mar 10Should Weakness in Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Feb 01
Here's What You Should Know About Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) 4.2% Dividend Yield
Jan 05Estimating The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)
Dec 10Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 4111's short term assets (NT$816.1M) exceed its short term liabilities (NT$481.1M).
Uzun Vadeli Yükümlülükler: 4111's short term assets (NT$816.1M) exceed its long term liabilities (NT$101.6M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 4111 has more cash than its total debt.
Borcun Azaltılması: 4111's debt to equity ratio has increased from 0% to 8.3% over the past 5 years.
Borç Kapsamı: 4111's debt is well covered by operating cash flow (131.8%).
Faiz Kapsamı: 4111 earns more interest than it pays, so coverage of interest payments is not a concern.